Myokines in metabolic homeostasis and diabetes


Physical activity exerts multiple beneficial effects and the myokine concept provides a framework for understanding the molecular pathways that integrate contracting muscle in the complex network of organ communication. This network includes multiple distinct and distal organs; however, the autocrine and paracrine effects of myokines within skeletal muscle (in which they are produced) also need specific attention. In humans, the functional allocation of myokines remains limited and recent findings on fibre type-specific myokine signatures point to an additional level of complexity. Myokines are involved in the anti-inflammatory effect of physical activity and, therefore, critically counteract insulin resistance and the metabolic perturbations of obesity and type 2 diabetes. Future work needs to address the role of myokines in concert with other crosstalk molecules, and to define their specific impact for metabolic homeostasis.



The beneficial effects of physical activity have been known for decades. However, only recently the so-called ‘myokine concept’ has generated a new understanding of the role that skeletal muscle plays as an active endocrine organ, which is involved in the communication and fine tuning between major metabolic organs [1,2,3]. The conceptual framework of considering myokines as critical mediators within the organ communication network has been instrumental in developing a new understanding of the molecular basis of physical activity. Given that physical activity undoubtedly represents a key preventive intervention for combating chronic diseases, such as type 2 diabetes and cardiovascular disease [4], extensive research has focused on the identification and functional characterisation of myokines, driven by expectations of finding novel preventative and therapeutic targets [5,6,7].

Although postulated for a long time, it was only ~20 years ago that the first exercise factor, IL-6, was identified and the term ‘myokine’ was introduced [8]. Some key facts about myokines are summarised in the Text box. The overarching property of all myokines is secretion or release from skeletal muscle cells. However, many myokines are not released into the circulation but act as autocrine or paracrine factors within skeletal muscle. In addition to myokines, metabolites released by contracting skeletal muscle play an important role as exercise factors [7]. For example, molecules released from skeletal muscle, such as β-aminoisobutyric acid [9] and lactate [10], were shown to convey signalling to the liver, adipose tissue and the brain [11]. This inter-organ metabolic crosstalk [12] is different from myokine-mediated crosstalk due to: (1) the protein-related high capacity of signalling information (covalent modification, protein folding); and (2) the involvement of specific receptors at the target cell. Secretomic studies of muscle cells have shown the presence of hundreds of myokines with mostly unknown functions [13], demonstrating the complexity of organ crosstalk.

This review aims to: (1) highlight the specific role of myokines in the network of organ communication, with specific relevance for humans; (2) consider the different stages of metabolic dysregulation and the role of myokines in these; and (3) address the translation of these findings to potential novel therapeutic strategies.

Exercise-induced myokines and the network of organ communication

The complexity of higher organisms requires a balanced system of cell-to-cell and organ-to-organ communication (organ crosstalk) to adapt and harmonise the physiological functions of different organs. Currently, the best understood element of organ crosstalk is represented by the secreted proteome of muscle, adipose tissue, liver and immune cells [14]. Initially, the adipocyte–myocyte axis was described as a paradigm of negative crosstalk between two tissues [15]. However, based on the myokine concept, a bi-directional crosstalk was proposed, leading to the current view of a network of organ communication. This is illustrated in Fig. 1, which emphasises known myokine targets and depicts key players in this interaction. In the sections below, I focus on the effects of exercise, which leads to metabolic adaptations in a number of distinct organs.

Fig. 1

The network of organ communication and the specific role of myokines. Both resistance and endurance training stimulate the release of a host of myokines from skeletal muscle; many of the myokines acting within the muscle as exercise factors are shown. Adipose tissue is a major target for the biological effects of myokines, including increased expression of adiponectin and white-to-brown transition of the tissue. Exercise-stimulated myokines also act on the liver although the release of hepatokines during exercise, such as fetuin-A and IGF-I, may be more important for improving metabolic performance. Muscle–bone crosstalk involves a number of different myokines that both positively and negatively modulate bone metabolism. The muscle–pancreas axis involves fibre type-specific myokines exerting beta cell protection. PPARα, peroxisome proliferator-activated receptor α. This figure is available as a downloadable slide

Muscle–adipose crosstalk

With the discovery of brown adipose tissue (BAT) in adult humans and the beneficial effects of this specific depot on metabolic homeostasis, an extensive number of studies addressed the question of whether exercise and certain myokines may promote BAT activity and the so-called browning of white fat [16]. In 2012, irisin was reported to be released from skeletal muscle after physical activity and to induce a white-to-brown transition in both rodents and humans, potentially mediating the beneficial effects of physical activity [17]. However, irisin remains one of the most controversial myokines, with its function still being ill-defined, especially in humans [18, 19]. In rodents, the transplantation of subcutaneous adipose tissue from trained to sedentary mice improved metabolic control, supporting the notion of exercise-induced adipose tissue adaptation [20]. As pointed out by Wright and co-workers [21], this is a complex process potentially involving a rise in catecholamines, activation of lipolysis, activation of AMP-activated protein kinase (AMPK), induction of mitochondrial biogenesis and browning. Interestingly, myokines such as IL-6 and the recently discovered meteorin-like protein, appear to be involved in this process [21]. In humans, the browning of white fat in response to exercise has remained controversial [22], thus requiring future studies on the functional impact of myokines on human adipose cells. Since only 5% of the myokinome is currently linked to a specific function, bioinformatic approaches will be needed to integrate the muscle–adipose crosstalk in the multi-organ communication network.

Muscle–liver crosstalk

Systematic reviews of the effect of exercise training on non-alcoholic fatty liver disease (NAFLD) suggest that exercise, independent of weight loss, ameliorates hepatic steatosis [23]. The role of myokines in this process has remained under-explored. Experimental data suggest that IL-6 upregulates hepatic peroxisome proliferator-activated receptor α (PPARα) and fatty acid oxidation. Most likely, the release of hepatokines in response to physical activity plays a key role in preventing the development of NAFLD. IGF-I and fibroblast growth factor (FGF)-21 are hepatokines that are upregulated in response to exercise in humans [24, 25] and the crosstalk between these molecules and muscle and adipose tissue improves metabolic performance and prevents the development of NAFLD. In a recent study, Drevon and co-workers [26] showed that long-term exercise improves insulin sensitivity by changing the circulating level of the hepatokine fetuin-A and NEFA, potentially involving a reduction in toll-like receptor 4 signalling.

Muscle–bone crosstalk

The tight functional association between muscle and bone is well known but, only recently, the ‘bone–muscle unit’ was described as a paradigm of multidirectional crosstalk between different tissues, involving not only muscle and bone but also adipose tissue, cartilage and tendon [27]. In this scenario, secreted myokines play an important role, most likely in a paracrine fashion [28], with IL-6 being confirmed to play a role in bone formation in human studies. Many other myokines affect bone metabolism either positively (e.g. IGF-I, FGF-2, IL-15) or negatively (e.g. TGF-β) [29].

Muscle–beta cell crosstalk

Several reports point to the existence of a muscle–pancreas axis, with myokines playing an important role in this crosstalk [30, 31]. This concept has been substantially reinforced by a recent study wherein a fibre type-specific myokine signature was demonstrated and the beta cell protective effect of angiogenin and osteoprotegerin (type II muscle-specific myokines) was reported [32]. Thus, it was shown that these tricep-specific myokines reduce apoptosis of beta cells. Specifically, both myokines prevent beta cell apoptosis induced by proinflammatory cytokines or by conditioned medium from insulin-resistant myotubes [32]. These observations are of general interest for the exercise and myokine field, and future studies need to address the impact of fibre type-specific myokines on organ crosstalk.

Metabolic dysregulation and the role of myokines

Persistent energy excess and an increased demand for lipid storage leads to adipocyte hypertrophy, cellular stress and low-grade chronic inflammation. As a result, obesity is characterised by an altered adipose tissue secretome that has a large impact on organ crosstalk, leading to insulin resistance and type 2 diabetes [14]. Physical inactivity is associated with a network of chronic diseases, including neurodegeneration, type 2 diabetes, cardiovascular disease, and different forms of cancer that involve enlargement of the visceral fat depot and induction of multiple systemic inflammatory pathways [33]. Moreover, physical inactivity, per se, is a major driver of metabolic disorders; the changes it induces in the muscle secretome and myokine profile most likely contribute to metabolic dysfunction, as evidenced by bed-rest studies, in which transcription of more than 4000 genes was found to be altered [34]. Given the existence of fibre type-specific myokine signatures, it can be anticipated that lack of exercise may compromise the regulatory crosstalk of the myokinome; however, this issue remains mostly unexplored.

Physical activity is known to exert an anti-inflammatory effect that, in addition to a reduction in body weight and visceral fat mass, may be due to an increased level in immune-modulatory agents, exerting a direct effect on the immune system [35]. Further, the paradigm myokine IL-6 is thought to induce an anti-inflammatory cascade by triggering the release of anti-inflammatory cytokines, such as IL-10, IL-1 receptor antagonist and soluble TNF receptor [3], jointly reducing systemic inflammation. At the local level, the novel myokine chitinase-3-like protein 1 (CHI3L1) was recently reported to exert an auto-protective function by inhibiting TNF-α-induced activation of NF-κB, inflammation and insulin resistance in myotubes [36]. These autocrine and paracrine functions of myokines and their regulation by exercise are presently underappreciated and future studies may identify myokines with potential therapeutic implications (see ‘Novel myokines as potential targets for diabetes therapy’ section, below).

An additional level of complexity surrounding the myokine field results from the different protocols used in studies of exercise training vs acute exercise (in laboratory settings), and the different findings obtained from human and rodent studies [6]. Moreover, some myokine studies have used a combination of endurance and strength training, with many different protocols of intensity and duration being used in these studies [6]. Furthermore, the number of myokines with proven functions in humans is very limited [6]; at present, robust data only exist for IL-6, IL-8, IL-13, IL-15, FGF-21, angiopoietin-like 4 (ANGPTL4), among a few others. Thus, the vast majority of myokines await functional assessment in humans. Consequently, more work is needed to integrate the myokine and inflammation network and to fully understand the role of myokines in metabolic dysregulation in humans.

Novel myokines as potential targets for diabetes therapy

The myokine concept has triggered extensive research efforts to identify novel myokines that might represent potential therapeutic targets to combat obesity and associated metabolic disorders.

Irisin gained considerable interest because it was claimed to increase thermogenesis and energy expenditure as a result of inducing the browning of white fat [17]. It is possible that irisin is present in the human circulation at very low concentrations, although the effect of exercise on irisin levels remains controversial. Spiegelman and colleagues reported a slight increase (20%) after 12 weeks of exercise [37]. However, a meta-analysis of randomised controlled studies showed a decrease in irisin levels after chronic exercise [38]. Given the lack of evidence for browning of white fat in humans in response to exercise [18], the function of irisin remains to be established.

FGF-21 is a protein preferentially expressed in the liver but is also described as being a myokine [39]. However, studies on the effect of exercise on FGF-21 have remained controversial [4]. The ability of FGF-21 to normalise glucose and lipid metabolism and to prevent the development of obesity and diabetes was first reported in 2005 [40]. Since then, the metabolic functions of FGF-21 have been studied in detail and it is now evident that this protein represents a paradigm for orchestrating the multi-organ crosstalk between fat, liver, brain and the vasculature [41]. FGF-21 stimulates glucose uptake in muscle and fat, the synthesis and release of adiponectin, and the white-to-brown shift of adipocytes leading to an increased energy expenditure. These beneficial properties raised substantial expectations that FGF-21 might represent a new target for diabetes therapy. However, native FGF-21 has a half-life (t1/2) of about 1 h and modifications of the molecule have been developed so that it may be administered as a drug [42]. Today, a new class of FGF-21 molecules is available, comprising analogues with an improved t1/2 [42]. A substantial number of these molecules is under development for the therapy of non-alcoholic steatohepatitis (NASH) and type 2 diabetes, and both Phase 1 and Phase 2 studies are currently ongoing.

Chemokine (C-X3-C motif) ligand 1 (CX3CL1; also referred to as fractalkine) is known to play a role in leucocyte adhesion. It has also been identified as a myokine with potential function in muscle injury and repair [43]. Interestingly, fractalkine was found to act as a novel player in regulating insulin secretion and beta cell function, and a recent study demonstrated that chronic administration of a long-acting fractalkine analogue caused persistent improvement of glucose tolerance, increased glucose-stimulated insulin secretion and reduced apoptosis of beta cells in different rodent models of obesity [44]. Due to an additional effect on hepatic insulin sensitivity, fractalkine may be of great interest for future development as a new agent for type 2 diabetes therapy.


Higher organisms need complex regulatory systems that contribute to adaptation and fine tuning of metabolic activities. The organ crosstalk network is an important component of this process and serves to communicate immediate and long-term information for functional adjustments in different tissues. Multiple signals are involved in this phenomenon and myokines are part of this information transmission pathway, certainly playing an important overall role in positive metabolic control. The myokine concept discussed in this paper has provided a new understanding of the role that skeletal muscle plays as an active endocrine organ. However, the precise understanding of myokine biology is currently hampered by the huge number of myokines mostly identified in cell cultures or animals. In humans, functional allocation of myokines has been very limited so far. Future directions should address the fibre type-specific myokine signatures and the autocrine and paracrine actions of myokines. This may provide new insight into muscle physiology and diseases such as cachexia and sarcopenia, both of which are under-explored areas in myokine research.

Muscle contraction and, thus, physical activity is a major regulator of myokine secretion, but physical activity and exercise training are part of a healthy lifestyle and the precise dissection of myokine action from other signalling events is very difficult. Myokines most likely act in an integrated way with metabolites, exosomes and other crosstalk signals. It may also be important to study individual myokine signatures to further explore the therapeutic value of certain myokines. As shown for irisin, a great deal of caution is required when extrapolating data obtained in rodent studies to humans. However, FGF-21 is a good example of an organokine that may turn out to be of great therapeutic value.



Brown adipose tissue


Fibroblast growth factor


Non-alcoholic fatty liver disease


  1. 1.

    Pedersen BK (2013) Muscle as a secretory organ. Compr Physiol 3(3):1337–1362.

    Article  PubMed  Google Scholar 

  2. 2.

    Pedersen BK, Åkerström TCD, Nielsen AR, Fischer CP (2007) Role of myokines in exercise and metabolism. J Appl Physiol 103(3):1093–1098.

    Article  CAS  PubMed  Google Scholar 

  3. 3.

    Pedersen BK, Febbraio MA (2008) Muscle as an endocrine organ: focus on muscle-derived interleukin-6. Physiol Rev 88(4):1379–1406.

    Article  CAS  PubMed  Google Scholar 

  4. 4.

    Eckardt K, Görgens SW, Raschke S, Eckel J (2014) Myokines in insulin resistance and type 2 diabetes. Diabetologia 57(6):1087–1099.

    Article  CAS  PubMed  Google Scholar 

  5. 5.

    Chung HS, Choi KM (2018) Adipokines and myokines: a pivotal role in metabolic and cardiovascular disorders. Curr Med Chem 25(20):2401–2415.

    Article  CAS  PubMed  Google Scholar 

  6. 6.

    Görgens SW, Eckardt K, Jensen J, Drevon CA, Eckel J (2015) Exercise and regulation of adipokine and myokine production. Prog Mol Biol Transl Sci 135:313–336

    Article  CAS  PubMed  Google Scholar 

  7. 7.

    Whitham M, Febbraio MA (2016) The ever-expanding myokinome: discovery challenges and therapeutic implications. Nat Rev Drug Discov 15(10):719–729.

    Article  CAS  PubMed  Google Scholar 

  8. 8.

    Pedersen BK, Steensberg A, Fischer C et al (2003) Searching for the exercise factor: is IL-6 a candidate? J Muscle Res Cell Motil 24(2/3):113–119.

    Article  CAS  PubMed  Google Scholar 

  9. 9.

    Roberts LD, Boström P, OʼSullivan JF et al (2014) β-Aminoisobutyric acid induces browning of white fat and hepatic β-oxidation and is inversely correlated with cardiometabolic risk factors. Cell Metab 19(1):96–108.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. 10.

    Morland C, Andersson KA, Haugen ØP et al (2017) Exercise induces cerebral VEGF and angiogenesis via the lactate receptor HCAR1. Nat Commun 8(1):15557.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. 11.

    Delezie J, Handschin C (2018) Endocrine crosstalk between skeletal muscle and the brain. Front Neurol 9:698.

    Article  PubMed  PubMed Central  Google Scholar 

  12. 12.

    Gancheva S, Jelenik T, Álvarez-Hernández E, Roden M et al (2018) Interorgan metabolic crosstalk in human insulin resistance. Physiol Rev 98(3):1371–1415.

    Article  CAS  PubMed  Google Scholar 

  13. 13.

    Hartwig S, Raschke S, Knebel B et al (2014) Secretome profiling of primary human skeletal muscle cells. Biochim Biophys Acta 1844(5):1011–1017.

    Article  CAS  PubMed  Google Scholar 

  14. 14.

    Romacho T, Elsen M, Röhrborn D, Eckel J (2014) Adipose tissue and its role in organ crosstalk. Acta Physiol 210(4):733–753.

    Article  CAS  Google Scholar 

  15. 15.

    Dietze D, Koenen M, Röhrig K, Horikoshi H, Hauner H, Eckel J (2002) Impairment of insulin signaling in human skeletal muscle cells by co-culture with human adipocytes. Diabetes 51(8):2369–2376.

    Article  CAS  PubMed  Google Scholar 

  16. 16.

    Leal LG, Lopes MA, Batista ML Jr (2018) Physical exercise-induced myokines and muscle-adipose tissue crosstalk: a review of current knowledge and the implications for health and metabolic diseases. Front Physiol 9:1307.

    Article  PubMed  PubMed Central  Google Scholar 

  17. 17.

    Bostrom P, Wu J, Jedrychowski MP (2012) A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 481(7382):463–468.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. 18.

    Elsen M, Raschke S, Eckel J (2014) Browning of white fat: does irisin play a role in humans? J Endocrinol 222(1):R25–R38.

    Article  CAS  PubMed  Google Scholar 

  19. 19.

    Albrecht E, Norheim F, Thiede B et al (2015) Irisin - a myth rather than an exercise-inducible myokine. Sci Rep 5(1):8889.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. 20.

    Stanford KI, Middelbeek RJ, Townsend KL et al (2015) A novel role for subcutaneous adipose tissue in exercise-induced improvements in glucose homeostasis. Diabetes 64(6):2002–2014.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. 21.

    Townsend LK, Knuth CM, Wright DC (2017) Cycling our way to fit fat. Physiol Rep 5(7):e13247.

    Article  PubMed  PubMed Central  Google Scholar 

  22. 22.

    Vosselman MJ, Hoeks J, Brans B et al (2015) Low brown adipose tissue activity in endurance-trained compared with lean sedentary men. Int J Obes 39(12):1696–1702.

    Article  CAS  Google Scholar 

  23. 23.

    Takahashi H, Kotani K, Tanaka K, Egucih Y, Anzai K (2018) Therapeutic approaches to nonalcoholic fatty liver disease: exercise intervention and related mechanisms. Front Endocrinol 9:588.

    Article  Google Scholar 

  24. 24.

    Rojas Vega S, Knicker A, Hollmann W, Bloch W, Strüder HK (2010) Effect of resistance exercise on serum levels of growth factors in humans. Horm Metab Res 42(13):982–986.

    Article  CAS  PubMed  Google Scholar 

  25. 25.

    Kim KH, Kim SH, Min YK, Yang HM, Lee JB, Lee MS (2013) Acute exercise induces FGF21 expression in mice and in healthy humans. PLoS One 8(5):e63517.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. 26.

    Lee S, Norheim F, Gulseth HL et al (2017) Interaction between plasma fetuin-A and free fatty acids predicts changes in insulin sensitivity in response to long-term exercise. Physiol Rep 5(5):e13183.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. 27.

    Tagliaferri C, Wittrant Y, Davicco MJ, Walrand S, Coxam V (2015) Muscle and bone, two interconnected tissues. Ageing Res Rev 21:55–70.

    Article  CAS  PubMed  Google Scholar 

  28. 28.

    Hamrick MW, McNeil PL, Patterson SL (2010) Role of muscle-derived growth factors in bone formation. J Musculoskelet Neuronal Interact 10(1):64–70

    CAS  PubMed  PubMed Central  Google Scholar 

  29. 29.

    Kaji H (2016) Effects of myokines on bone. Bonekey Rep 5:826

    Article  PubMed  PubMed Central  Google Scholar 

  30. 30.

    Bouzakri K, Plomgaard P, Berney T, Donath MY, Pedersen BK, Halban PA (2011) Bimodal effect on pancreatic β-cells of secretory products from normal or insulin-resistant human skeletal muscle. Diabetes 60(4):1111–1121.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. 31.

    Plomgaard P, Halban PA, Bouzakri K (2012) Bimodal impact of skeletal muscle on pancreatic β-cell function in health and disease. Diabetes Obes Metab 14(Suppl 3):78–84.

    Article  CAS  PubMed  Google Scholar 

  32. 32.

    Rutti S, Dusaulcy R, Hansen JS et al (2018) Angiogenin and osteoprotegerin are type II muscle specific myokines protecting pancreatic beta-cells against proinflammatory cytokines. Sci Rep 8(1):10072.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. 33.

    Pedersen BK (2011) Exercise-induced myokines and their role in chronic diseases. Brain Behav Immun 25(5):811–816.

    Article  CAS  PubMed  Google Scholar 

  34. 34.

    Alibegovic AC, Sonne MP, Højbjerre L et al (2010) Insulin resistance induced by physical inactivity is associated with multiple transcriptional changes in skeletal muscle in young men. Am J Physiol Endocrinol Metab 299(5):E752–E763.

    Article  CAS  PubMed  Google Scholar 

  35. 35.

    Drummond MJ, Timmerman KL, Markofski MM et al (2013) Short-term bed rest increases TLR4 and IL-6 expression in skeletal muscle of older adults. Am J Physiol Regul Integr Comp Physiol 305(3):R216–R223.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. 36.

    Görgens SW, Eckardt K, Elsen M, Tennagels N, Eckel J (2014) Chitinase-3-like protein 1 protects skeletal muscle from TNFα-induced inflammation and insulin resistance. Biochem J 459(3):479–488.

    Article  CAS  PubMed  Google Scholar 

  37. 37.

    Jedrychowski MP, Wrann CD, Paulo JA et al (2015) Detection and quantitation of circulating human irisin by tandem mass spectrometry. Cell Metab 22(4):734–740.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. 38.

    Qiu S, Cai X, Sun Z, Schumann U, Zügel M, Steinacker JM (2015) Chronic exercise training and circulating irisin in adults: a meta-analysis. Sports Med 45(11):1577–1588.

    Article  PubMed  Google Scholar 

  39. 39.

    Izumiya Y, Bina HA, Ouchi N, Akasaki Y, Kharitonenkov A, Walsh K (2008) FGF21 is an Akt-regulated myokine. FEBS Lett 582(27):3805–3810.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. 40.

    Kharitonenkov A, Shiyanova TL, Koester A et al (2005) FGF-21 as a novel metabolic regulator. J Clin Invest 115(6):1627–1635.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. 41.

    Jin L, Lin Z, Xu A (2016) Fibroblast growth factor 21 protects against atherosclerosis via fine-tuning the multiorgan crosstalk. Diabetes Metab J 40(1):22–31.

    Article  PubMed  PubMed Central  Google Scholar 

  42. 42.

    Sonoda J, Chen MZ, Baruch A (2017) FGF21-receptor agonists: an emerging therapeutic class for obesity-related diseases. Horm Mol Biol Clin Invest 30(2).

  43. 43.

    Catoire M, Mensink M, Kalkhoven E, Schrauwen P, Kersten S (2014) Identification of human exercise-induced myokines using secretome analysis. Physiol Genomics 46(7):256–267.

    Article  CAS  PubMed  Google Scholar 

  44. 44.

    Riopel M, Seo JB, Bandyopadhyay GK et al (2018) Chronic fractalkine administration improves glucose tolerance and pancreatic endocrine function. J Clin Invest 128(4):1458–1470.

    Article  PubMed  PubMed Central  Google Scholar 

Download references


The KomIT - Center of Competence for Innovative Diabetes Therapy is supported by EFRE.NRW and the EU. The German Diabetes Center is supported by the Ministerium für Wissenschaft und Forschung des Landes Nordrhein-Westfalen and the Bundesministerium für Gesundheit.

Author information




The author was the sole contributor to this paper.

Corresponding author

Correspondence to Jürgen Eckel.

Ethics declarations

The author declares that there is no duality of interest associated with this manuscript.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Figure slide

(PPTX 161 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Eckel, J. Myokines in metabolic homeostasis and diabetes. Diabetologia 62, 1523–1528 (2019).

Download citation


  • Diabetes
  • Exercise
  • Metabolic homeostasis
  • Myokines
  • Organ crosstalk
  • Physical activity
  • Review